Sitimagene ceradenovec

N/A

Report date: 2023/10/26 16:40:34

Base Information

Drug NameSitimagene ceradenovec
Drug Alias Name塞西马集CereproEG-009(Ark Therapeutics)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionGene transferenceThymidine kinase stimulants
TargetsThymidine kinase
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArk Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArk Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsGlioma

Other Information

ATC CodeL01XL01
Related LinksDrugBankKEGG